Healthcare Companies Worldwide

At LovedBy we (ethically + responsibly), co-create with young people, harness data, and build pioneering technology, to improve health outcomes and happiness of the next generation.

Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life.

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Our mission is to help patients of tick-borne diseases - especially Lyme borreliosis - get an earlier and more accurate diagnosis. Our breakthrough technology enables us to identify the infection directly from blood. Unlike other, indirect methods, we get a proof of infection directly, as early as a few weeks after the tick-bite, and even during or after a treatment. Having successfully finished clinical testing, DualDur (DD-LYME 4.0) method is soon going to be available across Europe. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 805609.

Our mission is to radically improve early detection of brain disorders. We combine Virtual Reality and Artificial Intelligence to empower ophthalmologists and neurologists with reliable measurements of eye and pupil movements. Our goal is to bring the diagnostic quality of highly trained tertiary care specialists where it is needed most, in primary and secondary care. 🏆 Ypsomed Innovation Award 2022 🏆 IMD Startup Competition 2022/23 🚀 Massachusettes Innovation Network, Global Eddies 2023

Mammaly, a pet health startup that develops a range of snacks specifically targeting and helping reduce the severity of aging dog issues.

Mcule operates chemical marketplaces for drug discovery complemented with services based around small-molecule compound sourcing. While the traditional Mcule database aggregates a wide variety of supplier catalogs, Mcule ULTIMATE database contains novel, synthetically accessible compounds. Mcule SynthAgora is a custom synthesis marketplace that enables our clients to receive offers conveniently for structures that are not available in any catalogs in the world.

MedBeat is a medical technology company establishing a modern solution to accurately monitor your heart activity everywhere and anytime during your everyday life. We are developing medical devices and software, with the purpose of monitoring and enhancing cardiac health.

Mediately helps doctors make better decisions by making medical knowledge accessible. Our mobile assistant, which helps diagnose faster and treat better, offers doctors and healthcare professionals agile and relevant medical information that can be accessible anywhere and anytime. The app can be downloaded in 10 European countries and is used by more than 200,000 doctors and 400,000 healthcare professionals. The tools in the app have been developed in accordance with the ISO 13485 standard for medical devices and the app is free of charge. Want to effectively present your products to 200,000+ MDs where and when it matters the most to them? Find out how at: https://pharma.mediately.co/ Or contact us at: sales@mediately.com

Medical Port is a medical travel provider dedicated to connect individuals with the best healthcare in private hospitals and clinics in Portugal. We ensure our clients the access to adequate, accurate and effective medical services in private providers in Portugal and the coordination of the whole medical travel process. Our goal is to provide foreigners with adequate options for medical care, gathering Portugal’s vast expertise in health care services, as well as the country’s renowned hospitality, on behalf of the clients whilst paying attention to the details that assure their well-being.

Founded in 2017, Meditopia is one of the world’s leading global mental health platforms and the global #1 App for non-English speaking countries. With over 35 million members in over 120 countries, Meditopia's content has been localized by experts in 12 different languages, to help you reduce stress and sleep better. Based out of vibrant Istanbul and across the globe, our team of expert mental health warriors are on a mission to bring peace of mind to even more people around the world, every day. Now more than ever. In 2021, Meditopia launched ‘Meditopia For Work’, a series of tailored mental health solutions for companies. Working already with over 100 businesses worldwide, our corporate solution provides services ranging from one-to-one coaching sessions with employees to comprehensive support to the HR teams in developing mental health programs tailored to their specific needs. You can visit www.meditopia.com/en/forwork/ to book your demo! Meditopia also loves to partner with brands that share similar values. Brand Collaborations can come from anywhere. Feel free to send us an email at partnerships@meditopia.com to connect.

At medlink we created a centralised locum tenens staffing system for hospitals. The platform connects hospitals with locum tenens and staffing agencies around Germany. Doctors and nurses can now be mobilised as quickly as possible - precisely tailored to the specific requirements. Learn more about our mission on www.medlink.de and get in touch to find out more.

Medudy is a healthcare start-up that makes medical education universal by using a doctor-centric streaming and learning platform for a modern global healthcare. We use artificial intelligence to provide physicians around the globe equal access to up-to-date and verified medical knowledge from top experts in multiple languages. We bring experts together, around the latest content and resources for the daily practice. We care for people, as we care for quality and make learning for doctors, very personal. The vision of this digital knowledge transfer is to optimize diagnostic and therapeutic procedures and ultimately improve patient care.

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.

Micrima was founded in 2006 to develop and commercialise microwave radar breast imaging technology initially pioneered at the University of Bristol in the UK. The company's MARIA system is currently in clinical trials to collect valuable data for our machine learning algorithm's. The latest step in the journey to Breast Screening will be launched in 2022. This new system will provide density information and improved ergonomics for patient and operator. Contact us to arrange to see this system or to find out more.

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

Citruslabs is the fastest-growing CRO (contract research organization) for consumer brands. Our mission is to provide brands with affordable clinical trials to create product claims. World-class supplement, skincare/cosmetic, superfood, and wellness brands are working with Citruslabs, such as HUM Nutrition, Saie Beauty, Supergut, Bite, Prima, Semaine, NakedPoppy, Disco, and many more. We bring together everything that is required to conduct and manage successful clinical trials, from study design to completion, offering our clients a hands-off, carefree approach to their clinical studies.

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.

Health technology company helping bipolar psychiatric patients to manage their diagnosis through continuous monitoring and data analytics.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

Minze Health is an Antwerp based HealthTech start-up that builds creative Digital Health solutions with a focus on Urology and Pelvic Health. Minze Homeflow enables the urologist to collect multiple uroflowmetries & voiding diary data in the comfort of the patients’ daily life and the allows the clinician to access this data in an online portal. Minze Hospiflow is a patient-friendly, flexible alternative for the current stationary uroflowmeters in hospitals or private practices. No more need for a dedicated space for uroflowmetry, Hospiflow can be used on any toilet!

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

Mode Sensors is a medical device company developing wearable sensor technology to support care providers and clinical decision-making.

MVision AI is a mission-oriented startup helping clinicians to save lives. MVision AI specializes in the field of medical imaging and artificial intelligence.

Mojo enables people to think about their fertility proactively to expand their future family-building potential and consciousness about their health. We provide them with access to an online fertility care platform that helps them test, understand and improve their fertility to start the family they long for - when they're ready.

Nature doesn’t need you. You need nature. Naava is a nature-inspired technology company from the Nordics. The global market leader in living green walls & biological indoor air purification with proprietary software & patented technology. We improve physical & mental health and connect you with nature. We have been recognized as one of Europe’s fastest-growing and hottest companies by Financial Times (2020), Inc (2018), and WIRED (2017). Naava creates the most compelling design furniture with living plants by combining nature, technology, and Scandinavian design. We are on a mission to re-seed the respect for nature and thus drive people and the planet towards healthier and more sustainable urban living. Experience the power of nature with Naava. For more information: https://linktr.ee/Naava.io

Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. Founded in 2004 on the breakthrough innovations by Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016. Navinci has also launched several daughter companies such as Olink Proteomics (noted Nasdaq NY: OLK) for high-throughput protein analysis in blood, Q-linea (noted on Nasdaq) focusing on counteracting antibiotic resistance in sepsis, and Halogenomics (acquired by Agilent) in target selection for next generation sequencing. Moreover, the company has outlicensed IP rights to several leading international life science companies. Navinci holds a broad and growing patent portfolio utilizing oligonucleotide-conjugated antibodies for detection of proteins and their interactions. From our base in Uppsala, Sweden, Navinci contributes to improve human health by serving scientist with sharp and tailored tools to study proteins and their interactions in order to understand human biology and develop better drugs.

Our immersive platform helps people understand the relationship between their cognitions, emotions, and actions and utilize the influence that one exerts on the other. With a data-driven algorithm combined with virtual reality technology, we continuously track user behavior over the course of their health-activating journey and generate the most personalized program to enhance their mental, physio-physical, or social and emotional skills.

NLC - the European Healthtech Venture Builder - is dedicated to advancing health, making it accessible for everyone. By using entrepreneurship at scale, our unique NLC approach allows us to find inventions, and create and support ventures that have the potential to reach the patient. Led by winning teams, together with a dedicated network and driven by data and learnings.

No Isolation is a company, dedicated to bringing people together through warm technology and knowledge. They have offices in London, Munich and Oslo. For children and young adult unable to attend school, No Isolation developed AV1, a telepresence robot designed to make it easy to attend school remotely. AV1 was launched in August 2016 and currently helps about 2000 children and young adults across Europe. For seniors and otherwise analogue people, the company designed Komp, a one-button computer designed to improve the communication between generations and family members, regardless of technological skills. Through Komp, seniors can receive messages, photos and video calls. As of today, close to 10 million moments have been shared between the Komp-app and Komps.

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

NutritionPro is an all-in-one service that professionally takes care of your nutrition by building, cooking and delivering a precise individual meal plan. Our mission is to improve human health, well-being and longevity worldwide by bringing nutritionist expertise to the masses.

We envision a world in which everybody, everywhere lives a life that is happier, healthier and longer. We're building a unique data platform that will enable healthier people and faster breakthroughs by learning from, personalising and adapting to every patient continuously. Our technology is a secure, compliant bridge between patients, healthcare providers and life sciences. It has full NHS integration with patients’ electronic medical health records and puts the patient in control of their data, enabling healthcare partners to build innovative patient support programmes across all therapeutic areas.

OpenUp is a Mental Well-Being Scale-up based in Amsterdam and Berlin. Our goal is to make mental well-being accessible to all. 🌱 Through our online platform, we offer employees the opportunity to book free, unlimited and anonymous consultations with psychologists - within 24 hours and in 20+ languages. In addition, we promote the discussion of mental well-being through various formats: - Mindfulness sessions (alone or in groups) - Group sessions to tackle challenges together - Masterclasses to learn more about mental health - Blogposts to learn more about current topics Through the unique combination of tech and human touch, we create meaningful, emotional connections with millions of people. 💡 In numbers: OpenUp works with over 750 companies in Europe, helping to improve the mental well-being of over 200.000 employees. Want to know more? Find out how OpenUp can support your organization and send us a message: www.openup.com/for-business

Optellum was founded so that every lung cancer patient is treated at the earliest possible stage, and cured. We are redefining early interception of lung disease, by enabling every clinician, in every hospital, to manage their patients in the optimal way. Our first product is the first Clinical Decision Support software for personalized early diagnosis & treatment of lung cancer, based on Artificial Intelligence & Machine Learning applied to the world’s largest clinical dataset. We are a team of world-leading medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision laboratory. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians (global authors of medical guidelines) and experts in deep learning. We are building up our development team – join our fight against cancer, working together with former software engineers from top technology companies (Amazon, Facebook, Redhat) and veterans of medical imaging startups. Learn more at http://www.optellum.com/.

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.

Ostoform Ltd. is an Irish-based company that is certified to ISO 13485 for the design, manufacture and supply of ostomy products. The multi-award-winning company was born out of a need to improve skin health and quality of life for people who have an ostomy. Extensive research, bench testing and clinical studies have culminated in the development of a patented platform technology which manages ostomy skin health by addressing issues relating to appliance absorbency and leakage. Ostoform can now proudly introduce the Ostoform Seal with FLOWASSIST Protection.

We empower everyone to change their eating and lifestyle-related habits, improving their long-term health through personalised support and technology. We partner with health insurers, healthcare systems, and doctors to provide everyone with easy access to the care they need.

Our Oxevision platform, a contact-free vision-based patient monitoring and management system for use in inpatient mental health settings, delivers clinical insights that enable staff to plan patient care and intervene proactively to help patients. Oxevision relays information to staff in real time by using an infrared sensitive camera housed in a secure unit installed in a patient’s room. It enables clinicians to take a patient's pulse and breathing rate measurements completely contact-free and take a short, 15-second remote safety check without disturbing their sleep. Through location and activity based alerts and warnings, Oxevision also notifies staff of activity that may indicate a patient needs help or assistance.

Oxipit is a computer vision software startup specialized in medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative Artificial Intelligence/Deep Learning breakthroughs to everyday clinical practice. Oxipit is the authors of CE certified multi-award winning ChestEye radiology imaging suite.

Unmind is the workplace wellbeing platform on a mission to create mentally healthy workplaces, where everyone can flourish. We partner with some of the world’s biggest brands (like Major League Baseball, Nationwide, Disney, Standard Chartered, Mediacom and British Airways) to give over 2.5 million people the right support at the right time. Unlike 95% of wellbeing solutions, we’re built on science. We take a whole organisation approach, giving people at all levels the tools they need to thrive.

ABCDx is revolutionising stroke management with the first mobile brain diagnostic platform that turns smartphones into medical devices. We equip healthcare providers with accessible tools to accurately diagnose stroke patients at point-of-care – and within only a few minutes. By pioneering the ability to decode chemical messages of the brain (brain biomarkers), we developed a clinically validated method to detect brain injury using just a single drop of blood from a finger prick. Interested to learn more or be part of the first mobile brain diagnostic platform? Our team would love to hear from you: https://www.abcdx.es/contact

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease. Finding a way to remain fit and active as we age isn’t just a personal imperative but also a global one. By 2050, one in four of us will be over 65 years old, the number of people age over 80 is projected to triple and retirement age to rise to 75-80 years old. As individuals and as a society, we need to find solutions to the problems of ageing. Our goal is to develop therapies that treat the most common MSK diseases, such as osteoarthritis, tendinopathy and lower back pain, re-defining what old age looks and feels like.

Intelligent Implants is a medical device company operating at the intersection of digital medicine and orthopedics. We develop innovative electrotherapeutic orthopedic devices to address significant unmet clinical needs. The company's SmartFuse® platform is a wirelessly enabled, active implant technology that uses an array of electrodes to stimulate, control, and monitor bone growth. Our mission is to leverage SmartFuse to develop a pipeline of smart orthopedic implants that can reduce healing times, engage patients & surgeons, enable digital surgery/robotics and ultimately improve outcomes for millions of patients.

Hertility is a women’s health company built by women, for women. We’re shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. We provide expert advice, education and access to care - all from the comfort of your home. Our research trials are a step towards fixing the currently flawed system. 31% of women will suffer from a reproductive health issue at some point and through our research, we aim to reduce the time to diagnosis through advanced at-home testing and specialist gynaecological care. We tailor pathways to the individual's reproductive goals, whether it be to explore their ovarian health and fertility options or overall hormonal health, such as confirming a PCOS diagnosis. Currently, we can diagnose 9 of the most common gynae pathologies which may lead to reduced fertility and signpost gynae cancers. Ultimately, our aim is to change attitudes around reproductive health, both for individuals and in the workplace, and to encourage women to be proactive by tracking their reproductive health. We’re calling this the Reproductive Revolution!

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta’s DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

Founded in 2020 by ex-management consultants from Accenture and McKinsey- we help people Reverse their Type 2 Diabetes. We are India's No.1 Clinically proven Diabetes reversal company, helping people lower their HbA1c and Blood glucose levels through lifestyle modification. What makes us unique is our ability to bring together the power of technology and human empathy to deliver measurable impact in our customers' lives. We use a combination of world-class coaches, nutrition experts, a gamified platform, and integrate our platform with rewards and recognition. The program revolves around cutting edge solutions in physical, mental and emotional well-being that unleash your true potential. Whenever you think fitness, nutrition, mindfulness programs, and counselling for mental health- think Breathe Well-being. Varsha Vaishnav VP - HR +91-8920863420 careeers@breathewellbeing.in

Briota is an award winning MedTech company committed to innovating tech solutions for remote care, diagnostics and management for chronic respiratory conditions. Briota was established in February 2018 with a mission of democratization of lung health solutions for patients with moderate to severe asthma and COPD conditions. Our AI first approach aims to simplify the diagnostics and lifecycle management of Chronic Respiratory Ailments in a post Covid-19 world. Briota’s innovative work in Prioritizing Care for Covid 19 patients using power of AI and ML has helped reduce Case Fatality Rate in patients with comorbidities. Government of India – Department of Science, BIRAC and Technology Development Board has funded R&D work of Briota. Briota’s Covid 19 Home Management service has benefitted over 15000 patients in Mumbai and currently is in implementation for over 40,000 workmen colony members in Tier II and Tier III cities like Renukoot, Hirakud, Utkal etc.

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. The Parkinson’s Foundation is recognized as number 33 in the top 50 nonprofits to work for by The NonProfit Times in the publication’s “2020 Best Nonprofits to Work For” list.